Clinical impact of (18)F fluorodeoxyglucose positron emission tomography in patients with non-small-cell lung cancer: a prospective study.

@article{Kalff2001ClinicalIO,
  title={Clinical impact of (18)F fluorodeoxyglucose positron emission tomography in patients with non-small-cell lung cancer: a prospective study.},
  author={Victor Kalff and Rodney J Hicks and Michael P Macmanus and David Sidney Binns and Allan F McKenzie and Robert E. Ware and Annette Hogg and David Ball},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2001},
  volume={19 1},
  pages={111-8}
}
PURPOSE To prospectively study the impact of (18)F fluorodeoxyglucose (FDG) positron emission tomography (PET) on clinical management of patients with non-small-cell lung cancer (NSCLC). PATIENTS AND METHODS One hundred five consecutive patients with NSCLC undergoing (18)F FDG PET were analyzed. Before PET, referring physicians recorded scan indication, conventional clinical stage, and proposed treatment plan. PET scan results were reported in conjunction with available clinical and imaging… CONTINUE READING

Connections & Topics

Mentioned Connections BETA
To prospectively study the impact of ( 18)F fluorodeoxyglucose ( FDG ) positron emission tomography ( PET ) on clinical management of patients with non - small - cell lung cancer ( NSCLC ) .
To prospectively study the impact of ( 18)F fluorodeoxyglucose ( FDG ) positron emission tomography ( PET ) on clinical management of patients with non - small - cell lung cancer ( NSCLC ) .
To prospectively study the impact of ( 18)F fluorodeoxyglucose ( FDG ) positron emission tomography ( PET ) on clinical management of patients with non - small - cell lung cancer ( NSCLC ) .
All Topics